Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Friedman, S. M. Articles by Drlica, K. Search for Related Content PubMed PubMed Citation Articles by Friedman, S. M. Articles by Drlica, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2001, p. 2378-2380, Vol. 45, No. 8
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.8.2378-2380.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Mutation in the DNA Gyrase A Gene of Escherichia coli That Expands the Quinolone Resistance-Determining Region

S. Marvin Friedman,^1,* Tao Lu,² and Karl Drlica²

Department of Biological Sciences, Hunter College of The City University of New York, New York, New York 10021,¹ and Public Health Research Institute, New York, New York 10016²

Received 25 January 2001/Returned for modification 13 March 2001/Accepted 2 May 2001

	ABSTRACT

Top Abstract Text References

In three Escherichia coli mutants, a change (Ala-51 to Val) in the gyrase A protein outside the standard quinolone resistance-determining region (QRDR) lowered the level of quinolone susceptibility more than changes at amino acids 67, 82, 84, and 106 did. Revision of the QRDR to include amino acid 51 is indicated.

	TEXT

Top Abstract Text References

The quinolones are antibacterial agents that act by forming ternary complexes with DNA gyrase and DNA topoisomerase IV on chromosomal DNA. Resistance to the compounds is generally associated with amino acid substitutions in portions of the GyrA (gyrase) and ParC (topoisomerase IV) proteins called the quinolone resistance-determining regions (QRDRs) (20). In Escherichia coli, the GyrA QRDR spans amino acids 67 to 106, with alteration at positions 83 and 87 often associated with clinical resistance (19). A similar association with resistance has been observed for a variety of pathogens (1, 6, 12, 16, 17), suggesting that resistance is due to altered drug targets. The use of fluoroquinolones that mitigate the protective effects of alterations at positions 83 and 87 (7, 21) may cause other alleles to assume a more important role in reducing the level of susceptibility (4). To help define additional sites that may contribute to resistance, we examined three nalidixic acid-resistant mutants of E. coli that are also thermotolerant (2, 3).

Independent, nalidixic acid-resistant (Nal^r) strains of E. coli CGSC 6353 (3) were obtained by selecting for growth on Luria-Bertani (LB) agar (9) containing 20 µg of nalidixic acid per ml, and members of the thermotolerant (T/r⁺) subset were identified by growth on LB agar plates at 48°C. These strains were designated MF1, MF3, and MF4-1; a Nal^r strain that lacked thermotolerance was designated MF13. Nal^r was mapped by P1-mediated transduction (18), DNA was isolated by phenol extraction, PCR was used to amplify regions of the gyrA gene, and nucleotide sequences in amplified regions were determined by automated sequencing. The protective effect of the gyrA mutations was compared by determining the fluoroquinolone concentration required to inhibit colony formation by 99% (MIC₉₉) rather than by standard MIC determinations to focus more sharply on bacteriostatic activity. For this measurement cells grown to the stationary phase in LB medium were diluted and applied to quinolone-containing agar plates; the colonies were counted after incubation at 37°C for 1 day. Preliminary determinations with twofold dilutions of the fluoroquinolone provided an approximate value for the MIC₉₉; a second measurement, plus a replicate, then used linear drug concentration increments that were 10 to 20% of the MIC₉₉. The numbers of colonies recovered were plotted against the drug concentration to determine the MIC₉₉ by interpolation.

P1-mediated transduction showed that a gyrA mutation was associated with nalidixic acid resistance. In this experiment a zfa-3145::Tn10 Kan^r marker, which is 70% cotransducible with gyrA, was first transferred by transduction from strain CAG 12183 (Nal^s Kan^r) (14) into strain MF4-1 (Nal^r T/r⁺). About 30% of the Kan^r transductants retained the Nal^r phenotype, indicating that a mutation at or near gyrA can confer nalidixic acid resistance. Then, the Nal^r marker was transferred into wild-type cells. Two Kan^r Nal^r transductants (KD1719 and KD1720) from the initial transduction were used to prepare phage lysates that were used to infect the parental Nal^s strain (CGSC 6353) and two other wild-type strains, DM4100 (15) and C600 (5). Cotransduction frequencies between Kan^r and Nal^r were 70, 80, and 70% for the three recipient strains, respectively. Thus, a mutation at or near gyrA was sufficient to confer nalidixic acid resistance.

The change associated with Nal^r in the gyrA QRDR was determined by nucleotide sequence analysis following PCR with primers 1037 and 1038 (Table 1). As shown in Table 2, the parental strain (CGSC 6353) had a predicted amino acid sequence identical to a sequence found in GenBank (accession no. X06744). In contrast, Nal^r T/r⁺ mutants (strains MF4-1, MF1, and MF3) contained a change that altered amino acid 51 from alanine to valine. The Nal^r mutant that was not thermotolerant, strain MF-13, had a 5' base change (G to T) in codon 87 expected to reduce the level of quinolone susceptibility by substituting tyrosine for aspartic acid (11).

View this table: [in this window] [in a new window]   TABLE 1.   Oligonucleotides used for PCR and sequence determination

View this table: [in this window] [in a new window]   TABLE 2.   Properties of nalidixic acid-resistant mutants

To determine whether a Nal^r T/r⁺ isolate contains additional changes in gyrA, we determined the sequence of the entire gene for parental (CGSC 6353) and mutant (MF4-1) strains. The gyrA gene was amplified with primers 1037 and 1042 (Table 1) and sequenced with primers 1043 through 1050 (Table 1). No further differences were observed between these two strains. Thus, an Ala-51-to-Val change in GyrA is sufficient to confer nalidixic acid resistance.

The Ala-51-to-Val substitution was neither necessary nor sufficient to confer thermotolerance: a Nal^s transductant of MF4-1 (strain KD1567) retained thermotolerance. Moreover, the Nal^r transductants of CGSC 6353, DM4100, and C600 were not thermotolerant: Nal^r transductants and their parental strains were indistinguishable with respect to growth on salt-free LB agar plates at both 43.5 and 46°C. In previous work (3), we reported that a plasmid-borne, wild-type gyrA gene suppressed both Nal^r and T/r⁺, suggesting that a GyrA alteration was necessary for thermotolerance. Suppression of thermotolerance by expression of GyrA from a plasmid probably arises from the presence of multiple copies of the gyrA gene. The genetic basis for thermotolerance remains unclear.

We compared the loss of quinolone susceptibility associated with the Ala-51-to-Val change to that seen with other GyrA variants. As shown in Fig. 1, Val-51 was associated with intermediate susceptibility to ciprofloxacin and gatifloxacin that was greater than that seen for four other amino acid changes generally considered to be within the QRDR (Ala-67 to Ser, Asp-82 to Ala, and Gln-106 to His). In the case of ciprofloxacin, this was also true for the Ala-84-to-Pro change. We conclude that the QRDR should be expanded to include position 51. 

View larger version (22K): [in this window] [in a new window]   FIG. 1.   Relative susceptibilites of gyrase mutants to fluoroquinolones. The MIC99s (see text) of ciprofloxacin (A) and gatifloxacin (B) were determined for a series of GyrA variants and are indicated above each bar (each determination was made twice with similar results). For illustrative purposes, the results for the mutant with the Ala-51-to-Val substitution are shown in white and are indicated by the arrows. All strains are gyrA Nalr transductants of wild-type strain DM4100, as described in the text or elsewhere (8). Amino acid changes in the GyrA QRDR and strain numbers (in parentheses) are as follows: S83L (KD66), A51V (KD1721), A67S (KD1911), G81C (KD1915), S83W (KD1909), D87N (KD1913), Q106H (KD1917), D82A (KD1973), A84P (KD1975), and D87Y (KD1977).

Examination of the crystal structure of the GyrA59 dimer (10) reveals that Ala-51 lies in helix 2, which is below the DNA recognition helix (helix 4; Fig. 2). Changes at positions 83 and 87 that cause the greatest loss in quinolone susceptibility are located on the surface of the recognition helix (Fig. 2), where quinolone binding may occur (8, 10, 13, 22). We speculate that the Ala-51-to-Val substitution distorts the region, altering its ability to interact with fluoroquinolones.

View larger version (58K): [in this window] [in a new window]   FIG. 2.   Structure of the GyrA59 dimer. The figure shows a ribbon representation (generated in RasMol) of the GyrA59 fragment (10), courtesy of J. G. Heddle (John Innes Centre, Norwich, United Kingdom). (A) The entire GyrA59 dimer. (B) An enlargement of the boxed region in panel A. Amino acids that change to confer quinolone resistance are indicated in black and by the amino acid numbers. Amino acid 51 is in helix 2, amino acid 67 is in helix 3, and amino acids 83 and 87 are in helix 4.

	ACKNOWLEDGMENTS

We thank Marila Gennaro, Jonathan Heddle, Anthony Maxwell, and Xilin Zhao for critical reading of the manuscript.

This work was supported by PSC-CUNY Faculty Research Award grants 66181 and 69197 to S.M.F. and by NIH grant AI35257 to K.D.

	FOOTNOTES

^* Corresponding author. Mailing Address: Department of Biological Sciences, Hunter College of The City University of New York, 695 Park Ave., New York, N.Y. 10021. Phone: (212) 772-5608. Fax: (212) 772-5227. E-mail: friedman{at}genectr.hunter.cuny.edu.

	REFERENCES

Top Abstract Text References

1.	Bachoual, R., L. Dubreuil, C.-J. Soussy, and J. Tankovic. 2000. Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin. Antimicrob. Agents Chemother. 44:1842-1845[Abstract/Free Full Text].
2.	Friedman, S. M., M. L. Droffner, and N. Yamamoto. 1991. Thermotolerant nalidixic acid-resistant mutants of Escherichia coli. Curr. Microbiol. 22:311-316.
3.	Friedman, S. M., M. Malik, and K. Drlica. 1995. DNA supercoiling in a thermotolerant mutant of Escherichia coli. Mol. Gen. Genet. 248:417-422[CrossRef][Medline].
4.	Ince, D., and D. Hooper. 2000. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob. Agents Chemother. 44:3344-3350[Abstract/Free Full Text].
5.	Jendrisak, J., R. Young, and J. Engel. 1978. In S. Berger, and A. Kimmel (ed.), Guide to molecular cloning techniques, p. 359-371. Academic Press, Inc., New York, N.Y.
6.	Jones, M. E., D. F. Sahm, N. Martin, S. Scheuring, P. Heisig, C. Thornsberry, K. Köhrer, and F.-J. Schmitz. 2000. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:462-466[Abstract/Free Full Text].
7.	Kitamura, A., K. Hoshino, Y. Kimura, I. Hayakawa, and K. Sato. 1995. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1467-1471[Abstract].
8.	Lu, T., X. Zhao, and K. Drlica. 1999. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activity by the C-8-methoxy group. Antimicrob. Agents Chemother. 43:2969-2974[Abstract/Free Full Text].
9.	Miller, J. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
10.	Morais-Cabral, J. H., A. P. Jackson, C. V. Smith, N. Shikotra, A. Maxwell, and R. C. Liddington. 1997. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388:903-906[CrossRef][Medline].
11.	Nakamura, S. 1997. Mechanisms of quinolone resistance. J. Infect. Chemother. 3:128-138.
12.	Schmitz, F.-J., A. Fluit, S. Brisse, J. Verhoef, K. Koher, and D. Milatovic. 1999. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol. 26:281-287[CrossRef][Medline].
13.	Sindelar, G., X. Zhao, A. Liew, Y. Dong, J. Zhou, J. Domagala, and K. Drlica. 2000. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob. Agents Chemother. 44:3337-3343[Abstract/Free Full Text].
14.	Singer, M., T. A. Baker, G. Schnitzler, S. M. Deischel, M. Goel, W. Dove, K. J. Jaacks, A. D. Grossman, J. W. Erickson, and C. A. Gross. 1989. A collection of strains containing genetically linked alternating antibiotic resistance elements for genetic mapping of Escherichia coli. Microbiol. Rev. 53:1-24[Abstract/Free Full Text].
15.	Sternglanz, R., S. DiNardo, K. A. Voelkel, Y. Nishimura, Y. Hirota, A. K. Becherer, L. Zumstein, and J. C. Wang. 1981. Mutations in the gene coding for Escherichia coli DNA topoisomerase I affecting transcription and transposition. Proc. Natl. Acad. Sci. USA 78:2747-2751[Abstract/Free Full Text].
16.	Sullivan, E. A., B. N. Kreiswirth, L. Palumbo, V. Kapur, J. M. Musser, A. Ebrahimzadeh, and T. R. Frieden. 1995. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345:1148-1150[CrossRef][Medline].
17.	Tanaka, M., H. Nakayama, M. Haraoka, T. Saika, I. Kobayashi, and S. Naito. 2000. Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in gyrA, with or without substitutions in parC, to newer fluoroquinolones and other antibiotics. Antimicrob. Agents Chemother. 44:192-195[Abstract/Free Full Text].
18.	Wall, J. D., and P. D. Harriman. 1974. Phage P1 mutants with altered transducing abilities for Escherichia coli. Virology 59:532-544[CrossRef][Medline].
19.	Yoo, J.-H., D.-H. Huh, J.-H. Choi, W.-S. Shin, J.-W. Kang, C.-C. Kim, and D. J. Kim. 1997. Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. Clin. Infect. Dis. 25:1385-1391[Medline].
20.	Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272[Abstract/Free Full Text].
21.	Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996[Abstract/Free Full Text].
22.	Zhou, J.-F., Y. Dong, X. Zhao, S. Lee, A. Amin, S. Ramaswamy, J. Domagala, J. M. Musser, and K. Drlica. 2000. Selection of antibiotic resistance: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525[CrossRef][Medline].

---

Antimicrobial Agents and Chemotherapy, August 2001, p. 2378-2380, Vol. 45, No. 8
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.8.2378-2380.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Spigaglia, P., Barbanti, F., Louie, T., Barbut, F., Mastrantonio, P. (2009). Molecular Analysis of the gyrA and gyrB Quinolone Resistance-Determining Regions of Fluoroquinolone-Resistant Clostridium difficile Mutants Selected In Vitro. Antimicrob. Agents Chemother. 53: 2463-2468 [Abstract] [Full Text]  
• Black, M. T., Stachyra, T., Platel, D., Girard, A.-M., Claudon, M., Bruneau, J.-M., Miossec, C. (2008). Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases. Antimicrob. Agents Chemother. 52: 3339-3349 [Abstract] [Full Text]  
• Spigaglia, P., Barbanti, F., Mastrantonio, P., Brazier, J. S., Barbut, F., Delmee, M., Kuijper, E., R. Poxton, I., on behalf of the European Study Group on Clostridi, (2008). Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57: 784-789 [Abstract] [Full Text]  
• Ostrov, D. A., Hernandez Prada, J. A., Corsino, P. E., Finton, K. A., Le, N., Rowe, T. C. (2007). Discovery of Novel DNA Gyrase Inhibitors by High-Throughput Virtual Screening. Antimicrob. Agents Chemother. 51: 3688-3698 [Abstract] [Full Text]  
• Malik, M., Hussain, S., Drlica, K. (2007). Effect of Anaerobic Growth on Quinolone Lethality with Escherichia coli. Antimicrob. Agents Chemother. 51: 28-34 [Abstract] [Full Text]  
• Huang, Y.-Y., Deng, J.-Y., Gu, J., Zhang, Z.-P., Maxwell, A., Bi, L.-J., Chen, Y.-Y., Zhou, Y.-F., Yu, Z.-N., Zhang, X.-E. (2006). The key DNA-binding residues in the C-terminal domain of Mycobacterium tuberculosis DNA gyrase A subunit (GyrA). Nucleic Acids Res 34: 5650-5659 [Abstract] [Full Text]  
• Ellington, M. J., Woodford, N. (2006). Fluoroquinolone resistance and plasmid addiction systems: self-imposed selection pressure?. J Antimicrob Chemother 57: 1026-1029 [Abstract] [Full Text]  
• Schmitz, G. E., Downs, D. M. (2006). An Allele of gyrA Prevents Salmonella enterica Serovar Typhimurium from Using Succinate as a Carbon Source.. J. Bacteriol. 188: 3126-3129 [Abstract] [Full Text]  
• Valdezate, S., Vindel, A., Saez-Nieto, J. A., Baquero, F., Canton, R. (2005). Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains. J Antimicrob Chemother 56: 220-223 [Abstract] [Full Text]  
• Lindgren, P. K., Marcusson, L. L., Sandvang, D., Frimodt-Moller, N., Hughes, D. (2005). Biological Cost of Single and Multiple Norfloxacin Resistance Mutations in Escherichia coli Implicated in Urinary Tract Infections. Antimicrob. Agents Chemother. 49: 2343-2351 [Abstract] [Full Text]  
• Rafii, F., Park, M., Novak, J. S. (2005). Alterations in DNA Gyrase and Topoisomerase IV in Resistant Mutants of Clostridium perfringens Found after In Vitro Treatment with Fluoroquinolones. Antimicrob. Agents Chemother. 49: 488-492 [Abstract] [Full Text]  
• Suda, N., Ito, Y., Imai, T., Kikumori, T., Kikuchi, A., Nishiyama, Y., Yoshida, S., Suzuki, M. (2004). The {alpha}4 residues of human DNA topoisomerase II{alpha} function in enzymatic activity and anticancer drug sensitivity. Nucleic Acids Res 32: 1767-1773 [Abstract] [Full Text]  
• Komp Lindgren, P., Karlsson, A., Hughes, D. (2003). Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections. Antimicrob. Agents Chemother. 47: 3222-3232 [Abstract] [Full Text]  
• Hurtle, W., Lindler, L., Fan, W., Shoemaker, D., Henchal, E., Norwood, D. (2003). Detection and Identification of Ciprofloxacin-Resistant Yersinia pestis by Denaturing High-Performance Liquid Chromatography. J. Clin. Microbiol. 41: 3273-3283 [Abstract] [Full Text]  
• Ruiz, J. (2003). Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51: 1109-1117 [Abstract] [Full Text]  
• Gross, C. H., Parsons, J. D., Grossman, T. H., Charifson, P. S., Bellon, S., Jernee, J., Dwyer, M., Chambers, S. P., Markland, W., Botfield, M., Raybuck, S. A. (2003). Active-Site Residues of Escherichia coli DNA Gyrase Required in Coupling ATP Hydrolysis to DNA Supercoiling and Amino Acid Substitutions Leading to Novobiocin Resistance. Antimicrob. Agents Chemother. 47: 1037-1046 [Abstract] [Full Text]  
• Ince, D., Zhang, X., Silver, L. C., Hooper, D. C. (2003). Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 274-282 [Abstract] [Full Text]  
• Ince, D., Zhang, X., Silver, L. C., Hooper, D. C. (2002). Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone. Antimicrob. Agents Chemother. 46: 3370-3380 [Abstract] [Full Text]  
• Pan, X.-S., Hamlyn, P. J., Talens-Visconti, R., Alovero, F. L., Manzo, R. H., Fisher, L. M. (2002). Small-Colony Mutants of Staphylococcus aureus Allow Selection of Gyrase-Mediated Resistance to Dual-Target Fluoroquinolones. Antimicrob. Agents Chemother. 46: 2498-2506 [Abstract] [Full Text]  
• Valdezate, S., Vindel, A., Echeita, A., Baquero, F., Canto, R. (2002). Topoisomerase II and IV Quinolone Resistance-Determining Regions in Stenotrophomonas maltophilia Clinical Isolates with Different Levels of Quinolone Susceptibility. Antimicrob. Agents Chemother. 46: 665-671 [Abstract] [Full Text]  
• Goni-Urriza, M., Arpin, C., Capdepuy, M., Dubois, V., Caumette, P., Quentin, C. (2002). Type II Topoisomerase Quinolone Resistance-Determining Regions of Aeromonas caviae, A. hydrophila, and A. sobria Complexes and Mutations Associated with Quinolone Resistance. Antimicrob. Agents Chemother. 46: 350-359 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Friedman, S. M. Articles by Drlica, K. Search for Related Content PubMed PubMed Citation Articles by Friedman, S. M. Articles by Drlica, K.